Document is current
Any future updates will be listed below
-
Authors
Abraham, Katharina https://orcid.org/0009-0008-0869-4920
Corro Ramos, Isaac https://orcid.org/0000-0002-1294-8187
Braal, C. Louwrens https://orcid.org/0000-0003-3600-9851
Feenstra, Talitha https://orcid.org/0000-0002-5788-0454
Kleijburg, Anne https://orcid.org/0000-0001-6223-3027
van Voorn, George A. K. https://orcid.org/0000-0002-1369-3964
Uyl-de Groot, Carin https://orcid.org/0000-0001-5808-302X
- License Information
-
More Information
Article History
Accepted: 23 March 2025
First Online: 28 April 2025
Declarations
:
: None of the authors received support from any organization for the submitted work.
: K.A., G.vV., T.F., A.K., C.UdG. and I.C.R. have no relevant financial or non-financial interests to disclose. C.L.B.: consultant for Eli Lilly, Daiichi Sankyo, CLB pharma consultancy (not during his work for this manuscript). All competing interest are outside the scope of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: K.A. and I.C.R. conceived the objective of the work. K.A. and I.C.R. performed the literature review. K.A. performed the data extraction, the analysis and drafted the article. I.C.R., G.vV., T.F., M.A., C.UdG., A.K. and C.L.B. critically and extensively revised the work. C.UdG. and I.C.R. supervised the work.
